
HTG Molecular Diagnostics HTGM
Annual report 2022
added 03-30-2023
HTG Molecular Diagnostics EV/EBITDA Ratio 2011-2026 | HTGM
Annual EV/EBITDA Ratio HTG Molecular Diagnostics
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.42 | -1.05 | -1.37 | -4.08 | -2.36 | -0.747 | -1.18 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.747 | -4.08 | -1.74 |
EV/EBITDA Ratio of other stocks in the Diagnostics research industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Agilent Technologies
A
|
27.4 | $ 121.02 | 1.7 % | $ 36.8 B | ||
|
Anixa Biosciences
ANIX
|
-2.25 | $ 2.96 | 4.71 % | $ 96.1 K | ||
|
Centogene N.V.
CNTG
|
0.387 | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
28.1 | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
-2.63 | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
-1.51 | $ 22.3 | -5.27 % | $ 234 M | ||
|
Celcuity
CELC
|
-2.38 | $ 111.31 | 3.64 % | $ 4.39 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
-73.4 | - | - | $ 562 M | ||
|
Co-Diagnostics
CODX
|
3.62 | - | - | $ 79.8 M | ||
|
Charles River Laboratories International
CRL
|
22 | $ 180.97 | 2.92 % | $ 8.97 B | ||
|
Castle Biosciences
CSTL
|
-21.2 | $ 28.14 | 2.07 % | $ 782 M | ||
|
Accelerate Diagnostics
AXDX
|
-5.56 | - | -61.36 % | $ 2.46 M | ||
|
DermTech
DMTK
|
-2.44 | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
-3.52 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-13.6 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-2.67 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-2.67 | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
2.58 | $ 14.14 | 2.56 % | $ 428 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
20.8 | - | - | $ 10.7 B | ||
|
Biodesix
BDSX
|
-4.25 | $ 14.71 | -5.1 % | $ 1.91 B | ||
|
Biocept
BIOC
|
-26.9 | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
141 | - | - | $ 1.31 B | ||
|
BioNano Genomics
BNGO
|
-7.71 | $ 1.14 | 1.88 % | $ 1.45 M | ||
|
IDEXX Laboratories
IDXX
|
45.3 | $ 650.0 | 2.28 % | $ 52.3 B | ||
|
Illumina
ILMN
|
70.5 | $ 129.59 | 0.02 % | $ 20.6 B | ||
|
Quest Diagnostics Incorporated
DGX
|
5.51 | $ 208.63 | 0.13 % | $ 23.2 B | ||
|
Danaher Corporation
DHR
|
20.1 | $ 205.32 | 0.63 % | $ 146 B | ||
|
Organovo Holdings
ONVO
|
0.992 | - | -2.3 % | $ 19.4 M | ||
|
Exact Sciences Corporation
EXAS
|
-20.8 | $ 103.51 | 0.13 % | $ 19.5 B | ||
|
Bioventus
BVS
|
26.4 | $ 8.42 | -3.66 % | $ 527 M | ||
|
DarioHealth Corp.
DRIO
|
-1.05 | $ 9.65 | -6.26 % | $ 274 M | ||
|
DexCom
DXCM
|
39.5 | $ 73.39 | 0.42 % | $ 28.6 B | ||
|
Laboratory Corporation of America Holdings
LH
|
8.7 | $ 281.11 | -0.69 % | $ 23.4 B | ||
|
QIAGEN N.V.
QGEN
|
13.2 | - | - | $ 10.6 B | ||
|
Lantheus Holdings
LNTH
|
-187 | $ 77.74 | -1.4 % | $ 5.25 B | ||
|
ICON Public Limited Company
ICLR
|
38 | $ 110.81 | 1.94 % | $ 9.14 B | ||
|
CareDx, Inc
CDNA
|
-100 | $ 19.28 | 2.56 % | $ 1.03 B | ||
|
Chembio Diagnostics
CEMI
|
-1.23 | - | 0.22 % | $ 16.8 M | ||
|
Motus GI Holdings
MOTS
|
0.351 | - | -34.28 % | $ 263 K | ||
|
Check-Cap Ltd.
CHEK
|
-0.674 | - | - | $ 9.42 M | ||
|
Mettler-Toledo International
MTD
|
827 | $ 1 290.77 | -1.92 % | $ 26.6 B | ||
|
Guardant Health
GH
|
-28.8 | $ 93.95 | 0.7 % | $ 11.8 B | ||
|
Myriad Genetics
MYGN
|
-17.2 | $ 5.35 | 1.04 % | $ 495 M | ||
|
IQVIA Holdings
IQV
|
24.1 | $ 177.49 | 2.0 % | $ 30.5 B | ||
|
Brainsway Ltd.
BWAY
|
-43.6 | $ 12.53 | 8.11 % | $ 99.4 M | ||
|
NeoGenomics
NEO
|
-33.5 | $ 9.14 | -4.25 % | $ 1.17 B | ||
|
National Research Corporation
NRC
|
21 | $ 13.25 | -1.05 % | $ 325 M | ||
|
Enzo Biochem
ENZ
|
58.3 | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
-19.5 | $ 204.02 | -1.46 % | $ 20.1 B |